Labopharm's once-daily Trazodone failed to gain FDA approval because of manufacturing deficiencies cited by the agency at an Italian facility that produces an ingredient of the antidepressant. Despite the decision, Labopharm said it remains optimistic and will "continue to plan for commercialization of the product."

Full Story:

Related Summaries